However, abnormal CRMP2 hyperphosphorylation is an early event in AD progression (Cole et al., 2007) and occurs downstream of APP, but neither excessive Aβ42 peptide nor neurotoxicity alone are sufficient to promote it (Williamson et al., 2011). Here, DPYSL2 is linked to Alzheimer disease.